Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

This article is a text version of a Wall Street Journal newsletter published earlier today.

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Wells Fargo on May 30, 2025. The analyst firm set a price target for $580.00 expecting REGN to rise to within 12 ...

Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase ...

LOS ANGELES, CA – Regeneron Pharmaceuticals, Inc. and the Society for Science on May 17 announced that Krish Pai, 17, of Del Mar, California, received the second Regeneron Young Scientist Award ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...